Houston, United States
Mongoose Bio Inc., founded in 2023, is a cutting-edge, clinical-stage biopharmaceutical company specializing in precision oncology. With a core focus on pioneering first-in-class T cell receptor T cell (TCR-T) therapies, the company positions itself at the forefront of cancer treatment innovation.
Through its proprietary antigen discovery pipeline and sophisticated memory T cell reprogramming technology, Mongoose Bio is capable of targeting a wide array of both common and rare solid tumors with sustained immunoprotection. The integration of Generative Artificial Intelligence into their processes significantly enhances antigen discovery and T cell engineering, thus optimizing therapeutic efficacy.
Founded on the scientific research and intellectual property developed by Dr. Cassian Yee from the MD Anderson Cancer Center, Mongoose Bio holds an exclusive global license to advance and commercialize this therapy. Recently, the company secured a $10.62M seed investment led by the Cancer Prevention and Research Institute of Texas (CPRIT), underlining investor confidence in their innovative approach and market potential.
